CML Treatment in Gurugram
Chronic myeloid leukaemia is one of the clearest examples of how far cancer treatment has moved. For most people diagnosed today it is managed with a daily oral tablet rather than chemotherapy, with regular blood monitoring and an ordinary working life alongside it.
In summary
Short answer: CML is a chronic blood cancer driven by a single genetic change, the BCR-ABL fusion gene. It is usually treated with oral targeted therapy taken daily at home, and monitored with periodic blood tests rather than repeated hospital admissions.
- Who this page is for
- Patients recently diagnosed with chronic myeloid leukaemia, families supporting them, and anyone seeking a second opinion on CML treatment in Gurugram or Gurgaon
- Currently consults at
- American Oncology Institute, Gurugram
- OPD hours
- Monday to Saturday, 9:00 am - 6:00 pm
- Appointments
- +91 95606 83949
Key takeaways
- CML is not treated like most cancers — the standard approach is oral targeted therapy, not intravenous chemotherapy.
- Diagnosis rests on BCR-ABL testing from blood or bone marrow, which confirms CML and gives the baseline for monitoring.
- Monitoring is the treatment — regular BCR-ABL measurement shows whether the tablet is working, often long before symptoms would.
- Taking it every day matters — missed doses are one of the most common reasons response is lost.
- Related: see blood cancer treatment and targeted therapy.
What is CML?
Short answer: Chronic myeloid leukaemia is a cancer of the blood-forming cells in the bone marrow. It develops when a swap of genetic material between two chromosomes creates an abnormal fusion gene called BCR-ABL, which drives the uncontrolled production of white blood cells. Because that single driver is well understood, CML became one of the first cancers where treatment could be aimed directly at the cause rather than at dividing cells in general. Many people have no symptoms at diagnosis and are picked up on a routine blood count showing a high white cell count.
How is CML diagnosed?
Diagnosis usually begins with a blood count that shows a raised white cell count. Confirmation comes from testing for the BCR-ABL fusion gene, by cytogenetic analysis, FISH or PCR on blood or a bone marrow sample. A bone marrow examination also establishes the phase of the disease, which matters because the great majority of patients are diagnosed in the chronic phase, where treatment works best. That baseline BCR-ABL measurement then becomes the reference point against which every later result is compared.
How is CML treated with targeted therapy?
The standard treatment for chronic phase CML is a class of oral targeted drugs known as tyrosine kinase inhibitors, which block the abnormal BCR-ABL protein. They are taken by mouth, usually once daily, at home. For most patients this replaces conventional chemotherapy entirely. Which agent is chosen depends on the individual, including other medical conditions and how the disease behaves. Treatment decisions of this kind are made together with the patient, after the options and their trade-offs have been explained.
Why does monitoring matter so much?
CML is one of the few cancers where a blood test tells you precisely how well treatment is working. BCR-ABL levels are measured at intervals and compared against the baseline. A falling level indicates the drug is doing its job; a plateau or rise prompts a review, which might mean checking adherence, looking for drug interactions, testing for resistance, or considering a change of agent. This is why scheduled follow-up is not optional in CML, even when a patient feels completely well.
What about side effects and daily life?
Most people tolerate targeted therapy well enough to continue working and living normally, but side effects do occur and vary between agents. Commonly reported effects include fatigue, nausea, muscle cramps, fluid retention and changes in blood counts. Most are manageable with dose adjustment, supportive measures or a change of drug, and they should be reported rather than endured quietly. Any new or worsening symptom is worth raising at the next review, or sooner if it is severe.
Why adherence is part of the treatment
Because the tablet is taken at home, day after day, for years, adherence becomes a clinical issue in its own right. Missing doses, particularly repeatedly, is a recognised reason for losing a response that had previously been good. Practical routines help: linking the dose to a fixed daily habit, using a pill organiser or a phone reminder, and planning ahead for travel. If side effects are the reason doses are being skipped, that is a conversation to have with the treating doctor, not a problem to manage alone.
When should I consider a second opinion?
Reasonable moments include soon after diagnosis and before starting long-term therapy, if BCR-ABL levels are not falling as expected, if side effects are affecting daily life, or if stopping treatment is being discussed. A second opinion here is a review of the diagnosis, the phase, the monitoring results and the treatment plan — and a confirmation that the current plan is sound is a useful outcome in itself.
Consulting in Gurugram
Dr. Sandeep Ramawat currently consults at the American Oncology Institute, Gurugram. OPD hours are Monday to Saturday, 9:00 am - 6:00 pm. Please bring your biopsy report, imaging and any prior treatment records to the first visit.
Appointments: +91 95606 83949 · drsandeepramawat@gmail.com
Frequently asked questions
Short answer: CML is generally described as controllable rather than routinely curable. For many patients, daily targeted therapy keeps the disease at very low levels for years. Some patients who achieve and sustain a deep response may be considered for carefully monitored treatment-free remission under specialist supervision, but that is an individual decision made on the evidence for that patient, not a guaranteed outcome.
Short answer: Most people with chronic phase CML do not receive conventional chemotherapy. The standard approach is oral targeted therapy. Other treatments, including transplant, are reserved for specific situations such as resistance to therapy or more advanced phases of the disease.
BCR-ABL is the abnormal fusion gene that drives CML. It is tested at diagnosis to confirm the disease and then repeatedly during treatment because the level in the blood is a direct measure of how well the treatment is working, usually well before any change in symptoms.
Many people do. Because treatment is a daily tablet taken at home and monitoring is periodic rather than constant, most patients in chronic phase continue working and normal activity. Side effects vary between individuals and agents, and are managed as they arise.
Occasional missed doses are common, but repeated missed doses are one of the recognised reasons a good response is lost. If adherence is difficult, whether because of side effects, cost or routine, it is important to raise it at review so the plan can be adjusted rather than quietly failing.
It is reasonable at any point, and particularly at diagnosis, when monitoring results are not as expected, or before a major change such as stopping therapy. Bring your blood counts, BCR-ABL results, bone marrow report and current prescriptions.
Speak to Dr. Ramawat
Dr. Ramawat currently consults at the American Oncology Institute, Gurugram. Call directly or send your details on WhatsApp.